Program
alisertib
Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.
Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 200 open or running | phase 3since Nov 28, 2011 | Jul 12, 2007 | none ahead |
| Puma Biotechnology | 33 open or running | phase 2since Sep 27, 2023 | Sep 27, 2023 | Oct 30, 2027phase 2 · NCT06095505 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Jul 6, 2014 | Jul 6, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jul 12, 2007.
- Nov 28, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralTakeda · NCT01482962 · 271 enrolled · United States, Australia, Austria and more
- Jan 13, 2012Phase 1 study in LymphomaTakeda · NCT01512758 · 36 enrolled · Singapore
- Jun 1, 2012Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01613261 · United States
- Oct 17, 2012Phase 1 study in LymphomaTakeda · NCT01714947 · 3 enrolled · United States
- Apr 29, 2013Phase 1 study in LymphomaTakeda · NCT01844583 · 55 enrolled · United States
- Jul 1, 2013Phase 1 study in LymphomaTakeda · NCT01898078 · 26 enrolled · United States
- Dec 4, 2013Phase 2 study in Small Cell Lung CarcinomaTakeda · NCT02038647 · 178 enrolled · United States, Belgium, Canada and more
- Jul 6, 2014Sarah Cannon Research Institute's first study: phase 2 study in Breast NeoplasmsNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT02187991 · 169 enrolled · United States
- Jul 30, 2014Phase 1 study in LymphomaTakeda · NCT02214147 · 36 enrolled · United States
- Oct 3, 2014Phase 1 study in LymphomaTakeda · NCT02259010 · 24 enrolled · United States
- Feb 11, 2015Phase 1 study in Ovarian NeoplasmsTakeda · NCT02367352 · 9 enrolled · Japan, Korea, Republic of
- Sep 27, 2023Puma Biotechnology's first study: phase 2 study in Small Cell Lung CarcinomaNew to Puma BiotechnologyPuma Biotechnology · NCT06095505 · 120 planned · United States
- Apr 12, 2024Phase 2 study in Breast NeoplasmsPuma Biotechnology · NCT06369285 · 225 planned · United States, Portugal, Spain
- Mar 6, 2026Phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT07465757 · 50 planned · United States, France, Spain
Ahead
- Oct 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT06095505
- Dec 30, 2027Primary completion: phase 2 study in Breast NeoplasmsPuma Biotechnology · NCT06369285
- Mar 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT07465757
TargetBeta
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07465757Small Cell Lung Carcinoma · United States, France, Spain | 2 | Recruiting | Puma Biotechnology | Mar 31, 2028 | 50 |
| NCT06369285Breast Neoplasms · United States, Portugal, Spain | 2 | Recruiting | Puma Biotechnology | Dec 30, 2027 | 225 |
| NCT06095505Small Cell Lung Carcinoma · United States | 2 | Recruiting | Puma Biotechnology | Oct 30, 2027 | 120 |
| NCT02367352Ovarian Neoplasms · Japan, Korea, Republic of | 1 | Terminated | Takeda | May 23, 2017 | 9 |
| NCT02259010Lymphoma · United States | 1 | Completed | Takeda | Mar 27, 2015 | 24 |
| NCT02214147Lymphoma · United States | 1 | Completed | Takeda | Apr 5, 2016 | 36 |
| NCT02187991Breast Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Apr 11, 2024 | 169 |
| NCT02038647Small Cell Lung Carcinoma · United States, Belgium, Canada and more | 2 | Completed | Takeda | Jan 3, 2016 | 178 |
| NCT01898078Lymphoma · United States | 1 | Completed | Takeda | Mar 5, 2014 | 26 |
| NCT01844583Lymphoma · United States | 1 | Completed | Takeda | Aug 4, 2014 | 55 |
| NCT01714947Lymphoma · United States | 1 | Completed | Takeda | Apr 4, 2013 | 3 |
| NCT01613261Advanced Nonhematologic Malignancies · United States | 1 | Withdrawn | Takeda | Sep 2015 | 0 |
| NCT01512758Lymphoma · Singapore | 1 | Completed | Takeda | Oct 8, 2013 | 36 |
| NCT01482962Lymphoma, T-Cell, Peripheral · United States, Australia, Austria and more | 3 | Completed | Takeda | Jun 30, 2015 | 271 |
| NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more | 2 | Completed | Takeda | Feb 5, 2015 | 45 |
| NCT01094288Advanced Solid Tumors · United States | 1 | Completed | Takeda | Feb 28, 2014 | 41 |
| NCT01045421Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Takeda | May 2013 | 273 |
| NCT00962091Advanced Solid Tumors · United States | 1 | Completed | Takeda | Dec 28, 2011 | 53 |
| NCT00853307Ovarian Neoplasms · United States | 2 | Completed | Takeda | Nov 23, 2009 | 31 |
| NCT00830518Leukemia, Myeloid, Acute · United States | 2 | Completed | Takeda | Feb 2, 2010 | 57 |
| NCT00807495Lymphoma, Large B-Cell, Diffuse · United States | 2 | Completed | Takeda | Jan 4, 2011 | 48 |
| NCT00697346Lymphoma, B-Cell, Marginal Zone · United States | 1 | Completed | Takeda | Oct 1, 2016 | 58 |
| NCT00651664Advanced Malignancies · Spain | 1 | Completed | Takeda | Sep 1, 2010 | 59 |
| NCT00500903Advanced Malignancies · United States | 1 | Completed | Takeda | Aug 1, 2010 | 87 |
How it is read
Names in the registry
- “Alisertib”, 23 entries
- “alisertib”, 2 entries
- “[^14C]-alisertib”, 1 entry
- “Alisertib (MLN8237)”, 1 entry
- “MLN8237 (Alisertib)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, 6 studies
- Small Cell Lung Carcinoma, 3 studies
- Breast Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.